BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 30983514)

  • 1. MiR-202-5p/
    Liu T; Guo J; Zhang X
    Cancer Biol Ther; 2019; 20(7):989-998. PubMed ID: 30983514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
    Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
    Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
    Fu X; Liu M; Qu S; Ma J; Zhang Y; Shi T; Wen H; Yang Y; Wang S; Wang J; Nan K; Yao Y; Tian T
    J Exp Clin Cancer Res; 2018 Mar; 37(1):52. PubMed ID: 29530052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.
    Miao Y; Zheng W; Li N; Su Z; Zhao L; Zhou H; Jia L
    Sci Rep; 2017 Feb; 7():41942. PubMed ID: 28165066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of microRNA-30a-5p inhibits liver cancer cell proliferation and induces apoptosis by targeting MTDH/PTEN/AKT pathway.
    Li WF; Dai H; Ou Q; Zuo GQ; Liu CA
    Tumour Biol; 2016 May; 37(5):5885-95. PubMed ID: 26589417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway.
    Gao X; Qin T; Mao J; Zhang J; Fan S; Lu Y; Sun Z; Zhang Q; Song B; Li L
    J Exp Clin Cancer Res; 2019 Jun; 38(1):256. PubMed ID: 31196157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27
    Wang DD; Yang SJ; Chen X; Shen HY; Luo LJ; Zhang XH; Zhong SL; Zhao JH; Tang JH
    Tumour Biol; 2016 Nov; 37(11):15315-15324. PubMed ID: 27699665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-425-5p promotes breast cancer cell growth by inducing PI3K/AKT signaling.
    Zhang LF; Zhang JG; Zhou H; Dai TT; Guo FB; Xu SY; Chen Y
    Kaohsiung J Med Sci; 2020 Apr; 36(4):250-256. PubMed ID: 31688991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms.
    Li C; Zheng X; Li W; Bai F; Lyu J; Meng QH
    BMC Cancer; 2018 Jan; 18(1):61. PubMed ID: 29316891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thidiazuron suppresses breast cancer via targeting miR-132 and dysregulation of the PI3K-Akt signaling pathway mediated by the miR-202-5p-PTEN axis.
    Ibrahim HM; Ismail MB; Ammar RB; Ahmed EA
    Biochem Cell Biol; 2021 Jun; 99(3):374-384. PubMed ID: 33103467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-205-5p regulates epithelial-mesenchymal transition by targeting PTEN via PI3K/AKT signaling pathway in cisplatin-resistant nasopharyngeal carcinoma cells.
    Zhang P; Lu X; Shi Z; Li X; Zhang Y; Zhao S; Liu H
    Gene; 2019 Aug; 710():103-113. PubMed ID: 31158447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
    Lu C; Shan Z; Hong J; Yang L
    Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation.
    Bahena-Ocampo I; Espinosa M; Ceballos-Cancino G; Lizarraga F; Campos-Arroyo D; Schwarz A; Maldonado V; Melendez-Zajgla J; Garcia‐Lopez P
    EMBO Rep; 2016 May; 17(5):648-58. PubMed ID: 27113763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling.
    Ding X; Xu X; He XF; Yuan Y; Chen C; Shen XY; Su S; Chen Z; Xu ST; Huang YH
    Bioengineered; 2021 Dec; 12(1):803-814. PubMed ID: 33648424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
    Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
    Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway.
    Wang F; Li L; Chen Z; Zhu M; Gu Y
    Int J Mol Med; 2016 May; 37(5):1421-8. PubMed ID: 26951965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
    Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
    Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation.
    Dastmalchi N; Safaralizadeh R; Hosseinpourfeizi MA; Baradaran B; Khojasteh SMB
    Mol Biol Rep; 2021 Feb; 48(2):1345-1357. PubMed ID: 33555529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-29a contributes to drug-resistance of breast cancer cells to adriamycin through PTEN/AKT/GSK3β signaling pathway.
    Shen H; Li L; Yang S; Wang D; Zhong S; Zhao J; Tang J
    Gene; 2016 Nov; 593(1):84-90. PubMed ID: 27523474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LINC00673 exerts oncogenic function in cervical cancer by negatively regulating miR-126-5p expression and activates PTEN/PI3K/AKT signaling pathway.
    Shi WJ; Liu H; Ge YF; Wu D; Tan YJ; Shen YC; Wang H; Xu H
    Cytokine; 2020 Dec; 136():155286. PubMed ID: 32950808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.